FDA approves Audenz as vaccine for a potential pandemic associated with H5N1 flu virus

Audenz is an adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic. It was developed with the MF59 adjuvant, which is believed to enhance an immune response from body by inducing antibodies against mutated virus strains

Biospace Inc.